10-K: Harmony Biosciences: WAKIX Drives Growth, Pipeline Expands

Harmony Biosciences reports strong 2025 revenue growth for WAKIX, expands its neuroscience pipeline, and navigates generic competition.

Summary

• Net product revenue for WAKIX increased by 21.5% to $868.5 million for the year ended December 31, 2025, compared to $714.7 million in 2024.
• WAKIX received FDA approval for the treatment of cataplexy in pediatric patients six years and older with narcolepsy in February 2026.
• The ZYN002 program for Fragile X Syndrome is being phased out, and the indication for 22q deletion syndrome is no longer being pursued, following the Phase 3 RECONNECT study not meeting its primary endpoint.
• Multiple ANDA litigations with generic manufacturers (Lupin, Novugen, Annora, MSN, Zenara/Hikma) were settled, granting licenses for generic entry starting July 2030 (or March 2030 for Hikma) if WAKIX receives pediatric exclusivity.
• The company initiated Phase 3 registrational studies for Pitolisant HD in narcolepsy (ONSTRIDE1) and idiopathic hypersomnia (ONSTRIDE2) in the fourth quarter of 2025, with topline data anticipated in 2027.
• Pitolisant GR pivotal bioequivalence study showed positive topline data in November 2025, supporting an NDA submission in early 2026 with a target PDUFA date in the first quarter of 2027.
• As of December 31, 2025, the company had $882.5 million in cash, cash equivalents, and investments, and $165.0 million in outstanding debt.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by strong WAKIX revenue growth and significant pipeline advancements, despite increased operating expenses and the discontinuation of the ZYN002 program.

Positives

• Net product revenue for WAKIX increased by 21.5% to $868.5 million in 2025, driven by an 18.3% increase in units shipped and a 7.0% price increase.
• WAKIX received FDA approval for the treatment of cataplexy in pediatric patients six years and older with narcolepsy in February 2026, expanding its approved indications.
• Positive topline data from the Pitolisant GR pivotal bioequivalence study confirmed bioequivalence to existing WAKIX tablets and supported initiating treatment at the therapeutic dose without titration.
• Initiated Phase 3 registrational studies (ONSTRIDE1 and ONSTRIDE2) for Pitolisant HD in narcolepsy and idiopathic hypersomnia, with utility patents filed potentially extending protection to the mid-2040s.
• Positive preclinical data for BP1.15205, an orexin 2 receptor agonist, demonstrated significant wake-promoting and cataplexy-suppressing effects.
• Initial open-label extension data from the ARGUS Study for EPX-100 (Dravet Syndrome) showed clinically meaningful reductions in seizure activity and a favorable benefit-risk profile.
• Successfully settled multiple ANDA litigations, securing generic entry dates in 2030 (or March 2030 for Hikma) contingent on pediatric exclusivity, providing intellectual property clarity.
• The One Big Beautiful Bill Act (OBBBA) enacted in July 2025 allows immediate expensing of domestic research and development expenses, resulting in a $48.0 million reduction to deferred tax assets.

Negatives

• The Pitolisant Phase 3 registrational study for idiopathic hypersomnia (IH) did not show a statistically significant difference compared to placebo, leading to a refusal-to-file letter for the sNDA in February 2025.
• The ZYN002 program in Fragile X Syndrome is being phased out, and the 22q deletion syndrome indication is no longer being pursued, due to the Phase 3 RECONNECT study not meeting its primary endpoint.
• Cost of product sales increased by 26.5% in 2025, and as a percentage of net product revenue, increased to 22.8% from 21.9% due to triggering a higher royalty tier under the 2017 LCA.
• General and administrative expenses increased by 38.2% ($42.2 million) in 2025, primarily due to a $39.0 million increase in legal and professional fees, including patent lawsuits and settlements.
• The One Big Beautiful Bill Act (OBBBA) imposes significant reductions in Medicaid program funding, which is expected to decrease enrollment and covered services, potentially adversely affecting WAKIX sales.
• The Inflation Reduction Act (IRA) requires manufacturers to engage in price negotiations with Medicare and imposes rebates for price increases that outpace inflation, likely impacting future revenues.
• Proposed Trump administration regulations (Globe and Guard) could implement mandatory payment models with rebates based on most favored nation pricing, representing a drastic and potentially negative shift for the U.S. pharmaceutical market.

Risks

• Substantial dependence on the commercial success of WAKIX; inability to maintain or increase sales would adversely affect revenue and financial condition.
• The continued commercial adoption of WAKIX and any other product candidates will depend on their market acceptance by physicians, patients, and payors.
• Reliance on license agreements with Bioprojet for core intellectual property relating to pitolisant; termination or loss of significant rights would adversely affect development and/or commercialization.
• Intense competition from numerous companies, many with greater resources, and rapid changes in science in the industry.
• Public health pandemics (e.g., COVID-19) may disrupt commercialization, clinical trials, manufacturing, and other business operations.
• Limited operating history and history of commercializing drugs may make it difficult to evaluate business success and future viability.
• May not be successful in identifying other indications for pitolisant or in-licensing/acquiring/discovering/developing/commercializing additional product candidates.
• The regulatory approval process of the FDA is costly, lengthy, and inherently unpredictable; failure to obtain approval for ongoing development programs would be substantially harmful.
• Failure to obtain and sustain an adequate level of coverage and reimbursement for WAKIX and other product candidates by third-party payors would adversely affect sales.
• May be required to make significant future payments to Bioprojet under licensing and collaboration agreements for pitolisant.
• Raising additional funds by issuing securities may cause dilution; debt financings may involve restrictive covenants; lending and licensing arrangements may restrict operations or require relinquishing proprietary rights.
• Risk of fines, penalties, or injunctions if determined to have promoted or be promoting the use of pitolisant for unapproved or off-label uses.
• Inability to obtain and maintain patent protection for technology and products, or insufficient scope of patent protection, may hinder effective competition.
• Failure to comply with obligations under license, collaboration, or other agreements may require payment of damages and loss of intellectual property rights.
• Directors, officers, and principal stockholders beneficially own a significant percentage of stock and can exert significant control over matters subject to stockholder approval.
• Future sales of common stock in the public market, including by directors, officers, or significant shareholders, could cause the share price to fall.
• Business, products, or product pricing could be subject to negative publicity, adversely affecting reputation, business, and financial condition.
• Reliance on third parties to conduct clinical trials, manufacture, and distribute products; failure to perform could delay or prevent commercialization.
• The market opportunity for WAKIX or any future product candidate may be smaller than estimated.
• Need to increase the size and capabilities of the organization, potentially leading to difficulties in managing growth.
• Future success depends on the ability to retain key executives and to attract, retain, and motivate qualified personnel.
• Adverse effects from natural disasters and failures of information technology systems, including real or perceived security breaches, loss of data, and other disruptions.
• Employees and independent contractors may engage in misconduct or other improper activities, including noncompliance with regulatory standards.
• Risks associated with operating internationally, including conflicting laws, political instability, and foreign currency exchange rate fluctuations.
• Failure to keep up with evolving laws, regulations, trends, and shareholder expectations relating to environmental, social, and governance (ESG) practices or reporting could adversely impact reputation, share price, and access to capital.
• The TLA Credit Agreement contains restrictive and financial covenants that may limit operating flexibility.
• Ability to utilize net operating loss carryforwards may be limited due to federal and state provisions.
• Changes in tax laws or regulations could adversely affect results of operations, business, and financial condition.
• WAKIX or any future product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, reduce commercial attractiveness, or result in negative consequences post-approval.
• FDA approval of generic versions of products, or failure to grant appropriate periods of exclusivity, could adversely affect sales.
• Interim, topline, and preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification procedures.
• Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or impossible by factors outside control.
• Even if orphan drug designation is received, the benefits, including marketing exclusivity, may not be maintained, potentially reducing product revenue.
• Ongoing regulatory obligations and continued regulatory review with respect to WAKIX will result in significant additional expense; WAKIX could be subject to labeling and other restrictions and market withdrawal.
• Business operations and relationships with healthcare professionals and payors are subject to applicable healthcare regulatory laws (e.g., Anti-Kickback Statute, False Claims Act), which could expose the company to penalties.
• Actual or perceived failure to comply with applicable data protection, privacy, and security laws, regulations, standards, and other requirements could adversely affect business.
• Clinical practice guidelines and recommendations published by various organizations could significantly influence the use of WAKIX.
• Future product candidates may be classified as controlled substances, subject to regulation by state, federal, and foreign law enforcement and other regulatory agencies.
• Enacted and future healthcare legislative changes (e.g., IRA, OBBBA) may increase the difficulty and cost for obtaining marketing approval and commercializing product candidates and affect prices.
• Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to review and approve products in a timely manner.
• No guarantee that FDA approval of EPX100 will result in the issuance of a priority review voucher, despite rare pediatric disease designation.
• Need to obtain FDA approval of any proposed product names; failure or delay could adversely affect business.
• The inventorship and ownership rights for patents that are in-licensed or owned may be challenged by third parties.
• Litigation or other proceedings to enforce or defend intellectual property rights are often very complex, expensive, and time-consuming, and may result in unfavorable outcomes.
• Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies.
• May need to acquire or license intellectual property from third parties, and such licenses may not be available or on commercially reasonable terms.
• May be subject to claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.
• Any trademarks obtained may be infringed or successfully challenged, resulting in harm to the business.

Future Outlook

The company anticipates topline data from the Pitolisant HD narcolepsy (ONSTRIDE1) and IH (ONSTRIDE2) studies in 2027, with a potential PDUFA date in 2028. An NDA submission for Pitolisant GR is targeted for early 2026, with a potential PDUFA date in the first quarter of 2027. Clinical PK data for BP1.15205 is expected in mid-2026. Sales and marketing expenses are projected to increase in the nearand mid-term to support WAKIX indications and portfolio expansion, alongside expected increases in general and administrative expenses for commercialization, R&D, and public company operations. The company believes its existing cash, cash equivalents, and investments will cover operational liquidity and potential investing activities for at least the next 12 months.

Management Comments

• "We are cultivating a differentiated neuroscience company, rooted in innovation and driven by a commitment to addressing the unmet needs of patients living with neurological diseases."
• "WAKIX has continued to reshape the treatment landscape for narcolepsy and remains the only FDA-approved treatment for narcolepsy that is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration (DEA)."
• "We believe that WAKIX offers a meaningfully differentiated product profile over current treatment options."
• "We remain committed to obtaining pediatric exclusivity for WAKIX."
• "We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees."
• "We believe that much of our success is rooted in the diversity of our teams and our commitment to inclusion."
• "Social responsibility has always been integral to our core values. We are committed to doing business with integrity and ethics."

Industry Context

StockSavvy.ai notes that Harmony Biosciences operates in the highly competitive and rapidly evolving rare neurological disorders market. The company's focus on non-scheduled treatments like WAKIX provides a distinct competitive advantage against controlled substances like Jazz Pharmaceuticals' Xyrem/Xywav and generic sodium oxybate, especially given WAKIX's lower pricing. However, it faces competition from other lower-priced stimulants and new entrants in the orexin agonist space (Takeda, Jazz/Sumitomo, Centessa, Alkermes). The company's pipeline expansion into rare epilepsy (Dravet, LGS) and neurobehavioral disorders (Fragile X, 22q deletion syndrome, though the ZYN002 program is being phased out) reflects a broader industry trend of diversifying portfolios to address significant unmet medical needs in specialized areas, while also navigating the inherent high risks of clinical development. The recent legislative changes like the Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act (OBBBA) highlight increasing governmental scrutiny on drug pricing and healthcare costs, which will impact the entire pharmaceutical industry, including Harmony Biosciences.

Comparison to Industry Standards

• WAKIX's non-scheduled status is a distinct competitive advantage compared to all other FDA-approved narcolepsy treatments (e.g., Jazz Pharmaceuticals' Xyrem/Xywav, Avadel's Lumryz, generic sodium oxybate, Axsome's Sunosi), which are controlled substances (Schedule II, III, or IV).
• WAKIX is priced lower than Xyrem, Xywav, Lumryz, and generic sodium oxybate, which is a competitive advantage for third-party payor preferences. Conversely, it is priced higher than other competitors such as Provigil (modafinil), Nuvigil (armodafinil), methylphenidate, and amphetamine.
• The U.S. narcolepsy market had an approximate net sales value of $3.1 billion in 2025, indicating a significant market opportunity where WAKIX is a key player.
• For Prader-Willi Syndrome (PWS), Vykat XR (diazoxide choline) by Soleno Therapeutics was approved in March 2025, representing a new competitor for Harmony's pitolisant in PWS. Other companies like Aardvark Therapeutics, Rhythm Pharmaceuticals, and Palobiofarma are also pursuing therapies.
• For Myotonic Dystrophy Type 1 (DM1), there are currently no FDA-approved treatments, positioning Harmony's pitolisant as a potential first-in-class therapy, but it faces competition from Avidity Biosciences, Vertex Pharmaceuticals, Entrada Therapeutic, and PepGen, Inc. in clinical development.
• For Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS), multiple FDA-approved therapies exist from companies like Jazz Pharmaceuticals, UCB, Biocodex, Eisai Co., Ltd., Janssen, GlaxoSmithKline, and Assertio Holdings. Harmony's EPX-100 enters a competitive landscape with established players and other pipeline candidates from Stoke Therapeutics, Encoded, Lundbeck, Bright Minds, and Praxis Precision Medicines.

Corporate Governance

Legal Proceedings

• ANDA litigation was initiated against Lupin Limited, Novugen Pharma Sdn. Bhd., Novitium Pharma LLC, Zenara Pharma Pvt. Ltd. (transferred to Hikma), and AET Pharma US, Inc. in response to their submissions seeking regulatory approval for generic versions of WAKIX before patent expiration.
• Settlement agreements were reached with Lupin (June 2025), Novugen (October 2024), Annora (March 2025), and MSN (January 2026), allowing generic entry starting July 2030 (or March 2030 for Hikma) if WAKIX receives pediatric exclusivity, or earlier under certain circumstances.
• Litigation against AET Pharma US, Inc. is ongoing, with a bench trial concluded in February 2026.
• Settlement amounts associated with ANDA litigation have been recognized in general and administrative expenses for the year ended December 31, 2025.

Related Party Transactions

• The company has a right-of-use agreement with Paragon Biosciences, LLC (a related party with common ownership and whose President/owner was the company's Chairman of the Board) for office space and consulting services, incurring $0.5 million in expenses in 2025.
• In June 2025, the company entered into a research collaboration, option and license agreement (CiRC Agreement) with CiRC Biosciences, Inc., an entity controlled by Paragon, paying an upfront fee of $15.0 million.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity issuances; significant control exerted by principal stockholders; risk of share price decline from future sales; reliance on stock price appreciation for gains as no dividends are planned.
• Patients: Continued focus on addressing unmet needs in rare neurological diseases; new treatment options through WAKIX pediatric approvals and pipeline candidates; potential impact of drug pricing legislation on access and affordability.
• Employees: Future success is highly dependent on attracting and retaining skilled employees; competitive compensation and benefits are provided; commitment to diversity and inclusion is emphasized.
• Third-party Payors: WAKIX sales are dependent on coverage and adequate reimbursement; increasing pressure for discounts and rebates due to cost containment initiatives and new legislation (IRA, OBBBA) could impact profitability.
• Suppliers/Manufacturers: Reliance on third-party manufacturers, including sole-source suppliers, for WAKIX and product candidates introduces supply chain risks.
• Bioprojet: Key licensing partner for pitolisant, with significant milestone and royalty payments due; potential for termination of agreements if obligations are not met.

Next Steps

• Submit New Drug Application (NDA) for Pitolisant GR in early 2026.
• Anticipate clinical PK data for BP1.15205 in mid-2026.
• Anticipate topline data from Pitolisant HD narcolepsy (ONSTRIDE1) and IH (ONSTRIDE2) studies in 2027.
• Target PDUFA date for Pitolisant GR in the first quarter of 2027.
• Potential PDUFA date for Pitolisant HD narcolepsy and IH programs in 2028.
• Evaluate a new formulation of pitolisant for fatigue in broader CNS indications, with multiple sclerosis (MS) as the lead, and explore opportunities in stroke and Parkinson's disease, focusing on formulation optimization and a Phase 1 PK study.
• Continue efforts to obtain pediatric exclusivity for WAKIX.
• Continue to evaluate HBS-102 in other pre-clinical experiments for additional potential indications.
• EPX-200 is currently in the pre-IND phase for developmental and epileptic encephalopathies (DEEs).
• Collaborate with CiRC Biosciences, Inc. on the research and development of CBS105 for treatment-resistant narcolepsy and CBS104 for refractory epilepsy.
• The company has an option to obtain an exclusive license for each of the CiRC Candidates.
• The UK adequacy decision for data transfers from EU member states to the UK will automatically expire in June 2025 unless re-assessed and renewed or extended.
• The Consolidated Appropriations Act of 2026 authorizes the FDA to award priority review vouchers through September 30, 2029.
• The company is evaluating the potential impact of its 'specified small manufacturer' status under the Inflation Reduction Act (IRA) on future revenues.
• The company is currently evaluating the impact that ASU 2024-03 (Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures) and ASU 2025-06 (Targeted Improvements to the Accounting for Internal-Use Software) will have on its consolidated financial statements.

Key Dates

Recommendation

Harmony Biosciences demonstrates robust revenue growth from WAKIX and a promising, diversified pipeline with several candidates advancing through clinical stages and recent FDA approvals. The successful resolution of multiple ANDA litigations provides some intellectual property clarity, pushing back generic entry. However, the discontinuation of the ZYN002 program, increasing operating expenses, and the ongoing challenges of drug pricing legislation (IRA, OBBBA) introduce notable headwinds. The company's reliance on WAKIX for a substantial portion of its revenue, coupled with the inherent risks of drug development and market competition, suggests a balanced "hold" position for investors, awaiting further clarity on pipeline successes and the long-term impact of pricing pressures.

Keywords

Harmony Biosciences, WAKIX, Pitolisant, Narcolepsy, Idiopathic Hypersomnia, Prader-Willi Syndrome, Myotonic Dystrophy Type 1, Rare Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Orexin 2 Receptor Agonist, BP1.15205, EPX-100, EPX-200, ZYN002, Fragile X Syndrome, SEC Filing, 10-K, Pharmaceutical, Biotechnology, Neuroscience, Orphan Drug, FDA Approval, Clinical Trials, Patent Litigation, Generic Drugs, Financial Results, Revenue Growth, Pipeline, Cybersecurity, ESG